NasdaqGS:IONSBiotechs
Is It Too Late to Consider Ionis After Its 126% Surge in 2025?
If you are wondering whether Ionis Pharmaceuticals is still worth considering after its huge run, or if the easy money has already been made, this breakdown is for you.
The stock has risen 125.9% year to date and is up 108.0% over the last year, even after a recent 0.6% slip over the past week and a 9.5% gain in the last month.
Those gains have come alongside growing optimism around its antisense drug pipeline and partnerships with major pharma names, as investors reassess the long term...